ME02416B - Trpv4 antagonisтi - Google Patents
Trpv4 antagonisтiInfo
- Publication number
- ME02416B ME02416B MEP-2016-120A MEP2016120A ME02416B ME 02416 B ME02416 B ME 02416B ME P2016120 A MEP2016120 A ME P2016120A ME 02416 B ME02416 B ME 02416B
- Authority
- ME
- Montenegro
- Prior art keywords
- methyl
- azaspiro
- oxa
- carbonitrile
- oxo
- Prior art date
Links
- 102000003567 TRPV4 Human genes 0.000 title 1
- 101150098315 TRPV4 gene Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 36
- 125000000217 alkyl group Chemical group 0.000 claims 34
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000001475 halogen functional group Chemical group 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 14
- 150000002431 hydrogen Chemical group 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 9
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 9
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- -1 SO2C1-3alkyl Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 6
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 6
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 6
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 6
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- KTFUKHNUUGSLQI-RRPNLBNLSA-N 3-[[(5r,7s)-7-methyl-2-oxo-3-[(1-phenyltriazol-4-yl)methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@]1(CCC[C@@](C1)(CN1C2=CC(=CC=C2N=C1)C#N)C)OC1=O)N1CC(N=N1)=CN1C1=CC=CC=C1 KTFUKHNUUGSLQI-RRPNLBNLSA-N 0.000 claims 1
- UYHVLESCFJXBNJ-BVZFJXPGSA-N 3-[[(5s,7s)-2-oxo-3-(thieno[2,3-b]pyridin-3-ylmethyl)-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC2=CC=C(C#N)C=C2N1C[C@H](C1)CCC[C@]11OC(=O)N(CC=2C3=CC=CN=C3SC=2)C1 UYHVLESCFJXBNJ-BVZFJXPGSA-N 0.000 claims 1
- FOGCMRDDKOPYNG-OOJDHBDPSA-N 3-[[(5s,7s)-2-oxo-3-[(1-pyridin-2-ylpyrrolidin-3-yl)methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(OC2=O)C[C@@H](CN3C4=CC(=CC=C4N=C3)C#N)CCC1)N2CC(C1)CCN1C1=CC=CC=N1 FOGCMRDDKOPYNG-OOJDHBDPSA-N 0.000 claims 1
- NAYBQFHMHDAHOR-DCFHFQCYSA-N 3-[[(5s,7s)-2-oxo-3-[(2-phenyl-1,3-thiazol-4-yl)methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(OC2=O)C[C@@H](CN3C4=CC(=CC=C4N=C3)C#N)CCC1)N2CC(N=1)=CSC=1C1=CC=CC=C1 NAYBQFHMHDAHOR-DCFHFQCYSA-N 0.000 claims 1
- RZGVISXWEANAMQ-DCFHFQCYSA-N 3-[[(5s,7s)-2-oxo-3-[(3-phenyl-1,2-oxazol-5-yl)methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(OC2=O)C[C@@H](CN3C4=CC(=CC=C4N=C3)C#N)CCC1)N2CC(ON=1)=CC=1C1=CC=CC=C1 RZGVISXWEANAMQ-DCFHFQCYSA-N 0.000 claims 1
- FTTXJXMCEDWXRE-DCFHFQCYSA-N 3-[[(5s,7s)-2-oxo-3-[(4-phenyl-1,3-thiazol-2-yl)methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(OC2=O)C[C@@H](CN3C4=CC(=CC=C4N=C3)C#N)CCC1)N2CC(SC=1)=NC=1C1=CC=CC=C1 FTTXJXMCEDWXRE-DCFHFQCYSA-N 0.000 claims 1
- UAGTZGZDHNEWNI-XLGQKKSSSA-N 3-[[(5s,7s)-2-oxo-3-[(5-phenylpyridin-3-yl)methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C([C@@]1(OC2=O)C[C@@H](CN3C4=CC(=CC=C4N=C3)C#N)CCC1)N2CC(C=1)=CN=CC=1C1=CC=CC=C1 UAGTZGZDHNEWNI-XLGQKKSSSA-N 0.000 claims 1
- QGDOIUKOAGUFDG-ZTOMLWHTSA-N 3-[[(5s,7s)-2-oxo-3-[(6-phenylpyridin-2-yl)methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(OC2=O)C[C@@H](CN3C4=CC(=CC=C4N=C3)C#N)CCC1)N2CC(N=1)=CC=CC=1C1=CC=CC=C1 QGDOIUKOAGUFDG-ZTOMLWHTSA-N 0.000 claims 1
- DKENCZNRDAGBFC-BVZFJXPGSA-N 3-[[(5s,7s)-2-oxo-3-[[1-[2-(trifluoromethyl)pyridin-4-yl]triazol-4-yl]methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(C(F)(F)F)=CC(N2N=NC(CN3C(O[C@@]4(C[C@@H](CN5C6=CC(=CC=C6N=C5)C#N)CCC4)C3)=O)=C2)=C1 DKENCZNRDAGBFC-BVZFJXPGSA-N 0.000 claims 1
- WFOIYBXIAUOWQQ-SIBVEZHUSA-N 3-[[(5s,7s)-2-oxo-3-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound FC(F)(F)C1=CC=CC(N2N=NC(CN3C(O[C@@]4(C[C@@H](CN5C6=CC(=CC=C6N=C5)C#N)CCC4)C3)=O)=C2)=C1 WFOIYBXIAUOWQQ-SIBVEZHUSA-N 0.000 claims 1
- DNMKAIHNGOJDPZ-SIBVEZHUSA-N 3-[[(5s,7s)-2-oxo-3-[[1-[4-(trifluoromethyl)phenyl]triazol-4-yl]methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=CC(C(F)(F)F)=CC=C1N1N=NC(CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=C1 DNMKAIHNGOJDPZ-SIBVEZHUSA-N 0.000 claims 1
- UEIQVXPZVSHVMS-BVZFJXPGSA-N 3-[[(5s,7s)-2-oxo-3-[[1-[5-(trifluoromethyl)pyridin-3-yl]triazol-4-yl]methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound FC(F)(F)C1=CN=CC(N2N=NC(CN3C(O[C@@]4(C[C@@H](CN5C6=CC(=CC=C6N=C5)C#N)CCC4)C3)=O)=C2)=C1 UEIQVXPZVSHVMS-BVZFJXPGSA-N 0.000 claims 1
- QTFSYDKDMPJZLJ-ZEQRLZLVSA-N 3-[[(5s,7s)-3-(1-ethyl-5-methylpyrazol-4-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CCN1N=CC(N2C(O[C@@]3(C[C@@](C)(CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=C1C QTFSYDKDMPJZLJ-ZEQRLZLVSA-N 0.000 claims 1
- AFRKSXHUNUAWNX-DQEYMECFSA-N 3-[[(5s,7s)-3-(1-tert-butylpyrazol-4-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NN(C(C)(C)C)C=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 AFRKSXHUNUAWNX-DQEYMECFSA-N 0.000 claims 1
- XEPGYSHKQBIYCM-ZEQRLZLVSA-N 3-[[(5s,7s)-3-(1-tert-butyltriazol-4-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound N1=NN(C(C)(C)C)C=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 XEPGYSHKQBIYCM-ZEQRLZLVSA-N 0.000 claims 1
- WKVMXLVJYFNQMV-DQEYMECFSA-N 3-[[(5s,7s)-3-(2,6-dimethoxypyridin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound COC1=NC(OC)=CC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 WKVMXLVJYFNQMV-DQEYMECFSA-N 0.000 claims 1
- MUAYDAHNXYQCMH-DQEYMECFSA-N 3-[[(5s,7s)-3-(2-methoxy-6-methylpyridin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound COC1=NC(C)=CC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 MUAYDAHNXYQCMH-DQEYMECFSA-N 0.000 claims 1
- BTSAVCILOALRKO-ZEQRLZLVSA-N 3-[[(5s,7s)-3-(2-methoxypyridin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound COC1=NC=CC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 BTSAVCILOALRKO-ZEQRLZLVSA-N 0.000 claims 1
- QYODVUSWWCYWOU-UIOOFZCWSA-N 3-[[(5s,7s)-3-(2-tert-butylpyrimidin-5-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(C(C)(C)C)=NC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 QYODVUSWWCYWOU-UIOOFZCWSA-N 0.000 claims 1
- RJVYNJUTWUJKFM-ZEQRLZLVSA-N 3-[[(5s,7s)-3-(2-tert-butyltriazol-4-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CC(C)(C)N1N=CC(N2C(O[C@@]3(C[C@@](C)(CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 RJVYNJUTWUJKFM-ZEQRLZLVSA-N 0.000 claims 1
- BKKHFQXUEPUWLP-GOTSBHOMSA-N 3-[[(5s,7s)-3-(3-chloropyridin-2-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(CCC[C@@](C1)(CN1C2=CC(=CC=C2N=C1)C#N)C)OC1=O)N1C1=NC=CC=C1Cl BKKHFQXUEPUWLP-GOTSBHOMSA-N 0.000 claims 1
- RJLSCTNIKNNESU-ZEQRLZLVSA-N 3-[[(5s,7s)-3-(3-cyclopropyl-1,2-oxazol-5-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(CCC[C@@](C1)(CN1C2=CC(=CC=C2N=C1)C#N)C)OC1=O)N1C(ON=1)=CC=1C1CC1 RJLSCTNIKNNESU-ZEQRLZLVSA-N 0.000 claims 1
- UQOKNVDJMMZPFW-GOTSBHOMSA-N 3-[[(5s,7s)-3-(3-ethyl-1,2-oxazol-5-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O1N=C(CC)C=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 UQOKNVDJMMZPFW-GOTSBHOMSA-N 0.000 claims 1
- BTTHQJFBAUMHQO-DQEYMECFSA-N 3-[[(5s,7s)-3-(3-methoxy-5-methylpyridin-2-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound COC1=CC(C)=CN=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 BTTHQJFBAUMHQO-DQEYMECFSA-N 0.000 claims 1
- PXMRWNDUICPMGO-ZEQRLZLVSA-N 3-[[(5s,7s)-3-(3-methoxypyridin-2-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound COC1=CC=CN=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 PXMRWNDUICPMGO-ZEQRLZLVSA-N 0.000 claims 1
- KOSAUXVCQPCSBE-DQEYMECFSA-N 3-[[(5s,7s)-3-(3-tert-butyl-1,2-oxazol-5-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O1N=C(C(C)(C)C)C=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 KOSAUXVCQPCSBE-DQEYMECFSA-N 0.000 claims 1
- PNSHSYAVAGSXBK-DQEYMECFSA-N 3-[[(5s,7s)-3-(3-tert-butyl-4-chloro-1,2-oxazol-5-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CC(C)(C)C1=NOC(N2C(O[C@@]3(C[C@@](C)(CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=C1Cl PNSHSYAVAGSXBK-DQEYMECFSA-N 0.000 claims 1
- IRLIJRWUACPNIW-FYSMJZIKSA-N 3-[[(5s,7s)-3-(3-tert-butyl-4-fluoro-1,2-oxazol-5-yl)-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CC(C)(C)C1=NOC(N2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=C1F IRLIJRWUACPNIW-FYSMJZIKSA-N 0.000 claims 1
- KHIDUNPTKCZCLM-UIOOFZCWSA-N 3-[[(5s,7s)-3-(3-tert-butyl-4-methyl-1,2-oxazol-5-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O1N=C(C(C)(C)C)C(C)=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 KHIDUNPTKCZCLM-UIOOFZCWSA-N 0.000 claims 1
- PGWJASHLWFNOMU-XDHUDOTRSA-N 3-[[(5s,7s)-3-(4,6-dimethoxypyridin-3-yl)-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(OC)=CC(OC)=C1N1C(=O)O[C@@]2(C[C@@H](CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 PGWJASHLWFNOMU-XDHUDOTRSA-N 0.000 claims 1
- MMNWTNHTOKUOIK-DQEYMECFSA-N 3-[[(5s,7s)-3-(4-bromo-3-tert-butyl-1,2-oxazol-5-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CC(C)(C)C1=NOC(N2C(O[C@@]3(C[C@@](C)(CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=C1Br MMNWTNHTOKUOIK-DQEYMECFSA-N 0.000 claims 1
- AKQIVKUXPFPXSB-ZEQRLZLVSA-N 3-[[(5s,7s)-3-(5-ethoxypyrazin-2-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(OCC)=CN=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 AKQIVKUXPFPXSB-ZEQRLZLVSA-N 0.000 claims 1
- ORNUGTMIWCFKMK-ZEQRLZLVSA-N 3-[[(5s,7s)-3-(5-methoxypyridin-2-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound N1=CC(OC)=CC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 ORNUGTMIWCFKMK-ZEQRLZLVSA-N 0.000 claims 1
- IDFKXMRIMYXRPU-UIOOFZCWSA-N 3-[[(5s,7s)-3-(5-tert-butyl-2-methylpyrazol-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CN1N=C(C(C)(C)C)C=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 IDFKXMRIMYXRPU-UIOOFZCWSA-N 0.000 claims 1
- QOCJWCNVDNWDOV-ZEQRLZLVSA-N 3-[[(5s,7s)-3-(6-chloro-4-methoxypyridin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound COC1=CC(Cl)=NC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 QOCJWCNVDNWDOV-ZEQRLZLVSA-N 0.000 claims 1
- ZYEGXBHPOTXFBP-ZEQRLZLVSA-N 3-[[(5s,7s)-3-(6-chloro-4-methylpyridin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CC1=CC(Cl)=NC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 ZYEGXBHPOTXFBP-ZEQRLZLVSA-N 0.000 claims 1
- HFYRWEVCCGNMHF-SVBPBHIXSA-N 3-[[(5s,7s)-3-(6-cyclopropyl-4-methoxypyridin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound N=1C=C(N2C(O[C@@]3(C[C@@](C)(CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)C(OC)=CC=1C1CC1 HFYRWEVCCGNMHF-SVBPBHIXSA-N 0.000 claims 1
- XGNQJOAXGTWMPJ-DQEYMECFSA-N 3-[[(5s,7s)-3-(6-ethoxy-4-methylpyridazin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound N1=NC(OCC)=CC(C)=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 XGNQJOAXGTWMPJ-DQEYMECFSA-N 0.000 claims 1
- HGERHERQHBJWIY-UIOOFZCWSA-N 3-[[(5s,7s)-3-(6-ethoxy-4-methylpyridin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(OCC)=CC(C)=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 HGERHERQHBJWIY-UIOOFZCWSA-N 0.000 claims 1
- ADKFYBLTZLMLQY-ZEQRLZLVSA-N 3-[[(5s,7s)-3-(6-ethoxypyridazin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound N1=NC(OCC)=CC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 ADKFYBLTZLMLQY-ZEQRLZLVSA-N 0.000 claims 1
- KNJVKNXKMLRURB-DQEYMECFSA-N 3-[[(5s,7s)-3-(6-ethoxypyridin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(OCC)=CC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 KNJVKNXKMLRURB-DQEYMECFSA-N 0.000 claims 1
- PNGJCXNXYWKYLW-UUOWRZLLSA-N 3-[[(5s,7s)-3-(6-methoxy-4-methylpyridin-3-yl)-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(OC)=CC(C)=C1N1C(=O)O[C@@]2(C[C@@H](CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 PNGJCXNXYWKYLW-UUOWRZLLSA-N 0.000 claims 1
- INGPNRAWWHYIRY-DQEYMECFSA-N 3-[[(5s,7s)-3-(6-methoxy-4-methylpyridin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(OC)=CC(C)=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 INGPNRAWWHYIRY-DQEYMECFSA-N 0.000 claims 1
- VHIZXXSODDXVCP-DQEYMECFSA-N 3-[[(5s,7s)-3-(6-methoxy-5-methylpyridin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=C(C)C(OC)=NC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 VHIZXXSODDXVCP-DQEYMECFSA-N 0.000 claims 1
- HHCYZEMVOFAUON-UIOOFZCWSA-N 3-[[(5s,7s)-3-(6-tert-butylpyridazin-3-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound N1=NC(C(C)(C)C)=CC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 HHCYZEMVOFAUON-UIOOFZCWSA-N 0.000 claims 1
- PTEOBTYDUZICJQ-QYBDOPJKSA-N 3-[[(5s,7s)-3-[(5-chloro-1-benzothiophen-3-yl)methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC2=CC=C(C#N)C=C2N1C[C@H](C1)CCC[C@@]1(OC1=O)CN1CC1=CSC2=CC=C(Cl)C=C21 PTEOBTYDUZICJQ-QYBDOPJKSA-N 0.000 claims 1
- XWFLVGMRDVJINT-DQEYMECFSA-N 3-[[(5s,7s)-3-[2-(2-hydroxypropan-2-yl)pyrimidin-5-yl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(C(C)(O)C)=NC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 XWFLVGMRDVJINT-DQEYMECFSA-N 0.000 claims 1
- JNXBRKBEYULTBB-MMTVBGGISA-N 3-[[(5s,7s)-3-[2-(3-cyclopentyl-1,2,4-oxadiazol-5-yl)-2-methylpropyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O([C@@]1(C[C@@H](CN2C3=CC(=CC=C3N=C2)C#N)CCC1)C1)C(=O)N1CC(C)(C)C(ON=1)=NC=1C1CCCC1 JNXBRKBEYULTBB-MMTVBGGISA-N 0.000 claims 1
- VDROKRSZXARPEI-BVZFJXPGSA-N 3-[[(5s,7s)-3-[2-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-methylpropyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CCC1=NOC(C(C)(C)CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 VDROKRSZXARPEI-BVZFJXPGSA-N 0.000 claims 1
- MEMLJXRSCHXKLF-PPHZAIPVSA-N 3-[[(5s,7s)-3-[2-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-2-methylpropyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CC(C)(C)C1=NOC(C(C)(C)CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 MEMLJXRSCHXKLF-PPHZAIPVSA-N 0.000 claims 1
- DLGLTVSFTYBQGD-BTRDEYTCSA-N 3-[[(5s,7s)-3-[2-[3-(1-ethoxyethyl)-1,2,4-oxadiazol-5-yl]-2-methylpropyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CCOC(C)C1=NOC(C(C)(C)CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 DLGLTVSFTYBQGD-BTRDEYTCSA-N 0.000 claims 1
- JKFYAOMKWIYBTD-XSQNJVOOSA-N 3-[[(5s,7s)-3-[2-[3-(1-methoxyethyl)-1,2,4-oxadiazol-5-yl]-2-methylpropyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound COC(C)C1=NOC(C(C)(C)CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 JKFYAOMKWIYBTD-XSQNJVOOSA-N 0.000 claims 1
- TWRHLUBNNGBBOU-BVZFJXPGSA-N 3-[[(5s,7s)-3-[2-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]-2-methylpropyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound COCC1=NOC(C(C)(C)CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 TWRHLUBNNGBBOU-BVZFJXPGSA-N 0.000 claims 1
- SZYBRYJCHHALBT-UUOWRZLLSA-N 3-[[(5s,7s)-3-[2-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CC1=NOC(C(C)(C)CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 SZYBRYJCHHALBT-UUOWRZLLSA-N 0.000 claims 1
- UBZADUKSIXWOAW-LGGPFLRQSA-N 3-[[(5s,7s)-3-[2-methyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)propyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O([C@@]1(C[C@@H](CN2C3=CC(=CC=C3N=C2)C#N)CCC1)C1)C(=O)N1CC(C)(C)C(ON=1)=NC=1C1=CC=CC=C1 UBZADUKSIXWOAW-LGGPFLRQSA-N 0.000 claims 1
- WIHJBDBGVRKHMP-SIBVEZHUSA-N 3-[[(5s,7s)-3-[2-methyl-2-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)propyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CC(C)C1=NOC(C(C)(C)CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 WIHJBDBGVRKHMP-SIBVEZHUSA-N 0.000 claims 1
- KODCLHXKXZXIET-PPHZAIPVSA-N 3-[[(5s,7s)-3-[2-methyl-2-(3-pyrimidin-5-yl-1,2,4-oxadiazol-5-yl)propyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O([C@@]1(C[C@@H](CN2C3=CC(=CC=C3N=C2)C#N)CCC1)C1)C(=O)N1CC(C)(C)C(ON=1)=NC=1C1=CN=CN=C1 KODCLHXKXZXIET-PPHZAIPVSA-N 0.000 claims 1
- PDZSNKDNEDXRBK-LGGPFLRQSA-N 3-[[(5s,7s)-3-[2-methyl-2-(5-phenyl-1,3,4-oxadiazol-2-yl)propyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O([C@@]1(C[C@@H](CN2C3=CC(=CC=C3N=C2)C#N)CCC1)C1)C(=O)N1CC(C)(C)C(O1)=NN=C1C1=CC=CC=C1 PDZSNKDNEDXRBK-LGGPFLRQSA-N 0.000 claims 1
- ZIJDHCDFIWYFMB-DCFHFQCYSA-N 3-[[(5s,7s)-3-[2-methyl-2-[3-(2-methylpropyl)-1,2,4-oxadiazol-5-yl]propyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CC(C)CC1=NOC(C(C)(C)CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 ZIJDHCDFIWYFMB-DCFHFQCYSA-N 0.000 claims 1
- PADMHWYWQSGFJM-MMTVBGGISA-N 3-[[(5s,7s)-3-[2-methyl-2-[3-(oxan-4-yl)-1,2,4-oxadiazol-5-yl]propyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O([C@@]1(C[C@@H](CN2C3=CC(=CC=C3N=C2)C#N)CCC1)C1)C(=O)N1CC(C)(C)C(ON=1)=NC=1C1CCOCC1 PADMHWYWQSGFJM-MMTVBGGISA-N 0.000 claims 1
- TXAJVDHOJTZASH-DCFHFQCYSA-N 3-[[(5s,7s)-3-[2-methyl-2-[3-(propan-2-yloxymethyl)-1,2,4-oxadiazol-5-yl]propyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CC(C)OCC1=NOC(C(C)(C)CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 TXAJVDHOJTZASH-DCFHFQCYSA-N 0.000 claims 1
- FHQZCYSNHHVYJQ-HJPURHCSSA-N 3-[[(5s,7s)-3-[2-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]propyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O([C@@]1(C[C@@H](CN2C3=CC(=CC=C3N=C2)C#N)CCC1)C1)C(=O)N1CC(C)(C)C1=NC(C(F)(F)F)=NO1 FHQZCYSNHHVYJQ-HJPURHCSSA-N 0.000 claims 1
- RTIARAJDTFZQDX-GMAHTHKFSA-N 3-[[(5s,7s)-3-[3-(1,1-difluoroethyl)-1,2-oxazol-5-yl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O1N=C(C(F)(F)C)C=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 RTIARAJDTFZQDX-GMAHTHKFSA-N 0.000 claims 1
- XEORZBWBTJYHNX-ZCYQVOJMSA-N 3-[[(5s,7s)-3-[3-(1-cyanocyclopropyl)-1,2-oxazol-5-yl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(CCC[C@@](C1)(CN1C2=CC(=CC=C2N=C1)C#N)C)OC1=O)N1C(ON=1)=CC=1C1(C#N)CC1 XEORZBWBTJYHNX-ZCYQVOJMSA-N 0.000 claims 1
- ROHFLSCJISFEEX-DQEYMECFSA-N 3-[[(5s,7s)-3-[3-(1-hydroxy-2-methylpropan-2-yl)-1,2-oxazol-5-yl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O1N=C(C(C)(CO)C)C=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 ROHFLSCJISFEEX-DQEYMECFSA-N 0.000 claims 1
- HOJRGZODESOWTN-DQEYMECFSA-N 3-[[(5s,7s)-3-[4-chloro-3-(2-cyanopropan-2-yl)-1,2-oxazol-5-yl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound N#CC(C)(C)C1=NOC(N2C(O[C@@]3(C[C@@](C)(CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=C1Cl HOJRGZODESOWTN-DQEYMECFSA-N 0.000 claims 1
- QXYGHNOMUADQSG-UIOOFZCWSA-N 3-[[(5s,7s)-3-[5-(1-hydroxy-2-methylpropan-2-yl)pyrazin-2-yl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(C(C)(CO)C)=CN=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 QXYGHNOMUADQSG-UIOOFZCWSA-N 0.000 claims 1
- URCMKDJBULWNAI-DQEYMECFSA-N 3-[[(5s,7s)-3-[5-(2-hydroxypropan-2-yl)pyrazin-2-yl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(C(C)(O)C)=CN=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 URCMKDJBULWNAI-DQEYMECFSA-N 0.000 claims 1
- FVGXAUYLGHDZHQ-VMPREFPWSA-N 3-[[(5s,7s)-3-[5-[2-(2-dimethylphosphoryloxyethoxy)propan-2-yl]pyrazin-2-yl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(C(C)(OCCOP(C)(C)=O)C)=CN=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 FVGXAUYLGHDZHQ-VMPREFPWSA-N 0.000 claims 1
- MRNAPMHFBPYVFY-NSOVKSMOSA-N 3-[[(5s,7s)-3-[5-[2-(2-methoxyethoxy)propan-2-yl]pyrazin-2-yl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC(C(C)(C)OCCOC)=CN=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 MRNAPMHFBPYVFY-NSOVKSMOSA-N 0.000 claims 1
- MUDAQAGUGSNTEW-VMPREFPWSA-N 3-[[(5s,7s)-3-[6-(5-fluoropyridin-2-yl)-4-methylpyridin-3-yl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound N=1C=C(N2C(O[C@@]3(C[C@@](C)(CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)C(C)=CC=1C1=CC=C(F)C=N1 MUDAQAGUGSNTEW-VMPREFPWSA-N 0.000 claims 1
- IQGKTSDYEAKCJR-QYBDOPJKSA-N 3-[[(5s,7s)-3-[[1-(3,5-difluorophenyl)triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound FC1=CC(F)=CC(N2N=NC(CN3C(O[C@@]4(C[C@@H](CN5C6=CC(=CC=C6N=C5)C#N)CCC4)C3)=O)=C2)=C1 IQGKTSDYEAKCJR-QYBDOPJKSA-N 0.000 claims 1
- VEQUFJQVNXQSSC-PPHZAIPVSA-N 3-[[(5s,7s)-3-[[1-(3-chloro-5-cyanophenyl)triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound ClC1=CC(C#N)=CC(N2N=NC(CN3C(O[C@@]4(C[C@@H](CN5C6=CC(=CC=C6N=C5)C#N)CCC4)C3)=O)=C2)=C1 VEQUFJQVNXQSSC-PPHZAIPVSA-N 0.000 claims 1
- KZSACMUDZZDILE-SIBVEZHUSA-N 3-[[(5s,7s)-3-[[1-(3-chlorophenyl)triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound ClC1=CC=CC(N2N=NC(CN3C(O[C@@]4(C[C@@H](CN5C6=CC(=CC=C6N=C5)C#N)CCC4)C3)=O)=C2)=C1 KZSACMUDZZDILE-SIBVEZHUSA-N 0.000 claims 1
- QJCSPJUDQHUBGO-PPHZAIPVSA-N 3-[[(5s,7s)-3-[[1-(3-cyano-5-fluorophenyl)triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound FC1=CC(C#N)=CC(N2N=NC(CN3C(O[C@@]4(C[C@@H](CN5C6=CC(=CC=C6N=C5)C#N)CCC4)C3)=O)=C2)=C1 QJCSPJUDQHUBGO-PPHZAIPVSA-N 0.000 claims 1
- HCTYFDLOVKVHSK-IDISGSTGSA-N 3-[[(5s,7s)-3-[[1-(3-cyanophenyl)triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(OC2=O)C[C@@H](CN3C4=CC(=CC=C4N=C3)C#N)CCC1)N2CC(N=N1)=CN1C1=CC=CC(C#N)=C1 HCTYFDLOVKVHSK-IDISGSTGSA-N 0.000 claims 1
- WMUOEIURPANJRT-SIBVEZHUSA-N 3-[[(5s,7s)-3-[[1-(3-fluorophenyl)triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound FC1=CC=CC(N2N=NC(CN3C(O[C@@]4(C[C@@H](CN5C6=CC(=CC=C6N=C5)C#N)CCC4)C3)=O)=C2)=C1 WMUOEIURPANJRT-SIBVEZHUSA-N 0.000 claims 1
- QYXGIAMYDNJMIA-DCFHFQCYSA-N 3-[[(5s,7s)-3-[[1-(3-methoxyphenyl)triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound COC1=CC=CC(N2N=NC(CN3C(O[C@@]4(C[C@@H](CN5C6=CC(=CC=C6N=C5)C#N)CCC4)C3)=O)=C2)=C1 QYXGIAMYDNJMIA-DCFHFQCYSA-N 0.000 claims 1
- CQKXQKLAULLWND-IDISGSTGSA-N 3-[[(5s,7s)-3-[[1-(3-methylphenyl)triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CC1=CC=CC(N2N=NC(CN3C(O[C@@]4(C[C@@H](CN5C6=CC(=CC=C6N=C5)C#N)CCC4)C3)=O)=C2)=C1 CQKXQKLAULLWND-IDISGSTGSA-N 0.000 claims 1
- MGGJIASIQQJNEY-SIBVEZHUSA-N 3-[[(5s,7s)-3-[[1-(4-chlorophenyl)triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1N=NC(CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=C1 MGGJIASIQQJNEY-SIBVEZHUSA-N 0.000 claims 1
- MVXFGELRKKKCLN-IDISGSTGSA-N 3-[[(5s,7s)-3-[[1-(4-cyanophenyl)triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(OC2=O)C[C@@H](CN3C4=CC(=CC=C4N=C3)C#N)CCC1)N2CC(N=N1)=CN1C1=CC=C(C#N)C=C1 MVXFGELRKKKCLN-IDISGSTGSA-N 0.000 claims 1
- GDXHRDONGTVEQX-IDISGSTGSA-N 3-[[(5s,7s)-3-[[1-(4-methylphenyl)triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=CC(C)=CC=C1N1N=NC(CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=C1 GDXHRDONGTVEQX-IDISGSTGSA-N 0.000 claims 1
- URERBFWHKBXPGE-BVZFJXPGSA-N 3-[[(5s,7s)-3-[[1-(5-chloropyridin-3-yl)triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound ClC1=CN=CC(N2N=NC(CN3C(O[C@@]4(C[C@@H](CN5C6=CC(=CC=C6N=C5)C#N)CCC4)C3)=O)=C2)=C1 URERBFWHKBXPGE-BVZFJXPGSA-N 0.000 claims 1
- UCZRIPDVPVVMCX-PPHZAIPVSA-N 3-[[(5s,7s)-3-[[1-[4-cyano-3-(trifluoromethyl)phenyl]triazol-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=C(C#N)C(C(F)(F)F)=CC(N2N=NC(CN3C(O[C@@]4(C[C@@H](CN5C6=CC(=CC=C6N=C5)C#N)CCC4)C3)=O)=C2)=C1 UCZRIPDVPVVMCX-PPHZAIPVSA-N 0.000 claims 1
- AVGAOELALDXVRL-PPHZAIPVSA-N 3-[[(5s,7s)-3-[[3-(4-chlorophenyl)-1,2-oxazol-5-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1=NOC(CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=C1 AVGAOELALDXVRL-PPHZAIPVSA-N 0.000 claims 1
- STLHKAFHEAPIBY-LGGPFLRQSA-N 3-[[(5s,7s)-3-[[4-(4-methoxy-3-methylphenyl)-1,3-thiazol-2-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=C(C)C(OC)=CC=C1C1=CSC(CN2C(O[C@@]3(C[C@@H](CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 STLHKAFHEAPIBY-LGGPFLRQSA-N 0.000 claims 1
- JFDKAWITNHVOIK-SVBPBHIXSA-N 3-[[(5s,7s)-7-methyl-2-oxo-3-(3-phenyl-1,2-oxazol-5-yl)-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(CCC[C@@](C1)(CN1C2=CC(=CC=C2N=C1)C#N)C)OC1=O)N1C(ON=1)=CC=1C1=CC=CC=C1 JFDKAWITNHVOIK-SVBPBHIXSA-N 0.000 claims 1
- BGWFPGSXVMEKMM-ZEQRLZLVSA-N 3-[[(5s,7s)-7-methyl-2-oxo-3-(3-prop-1-en-2-yl-1,2-oxazol-5-yl)-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O1N=C(C(=C)C)C=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 BGWFPGSXVMEKMM-ZEQRLZLVSA-N 0.000 claims 1
- QMDFYZGWKSODQN-ZEQRLZLVSA-N 3-[[(5s,7s)-7-methyl-2-oxo-3-(3-propan-2-yl-1,2-oxazol-5-yl)-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O1N=C(C(C)C)C=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 QMDFYZGWKSODQN-ZEQRLZLVSA-N 0.000 claims 1
- NULTZQPYYBAWCL-ZEQRLZLVSA-N 3-[[(5s,7s)-7-methyl-2-oxo-3-(pyridin-2-ylmethyl)-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(CCC[C@@](C1)(CN1C2=CC(=CC=C2N=C1)C#N)C)OC1=O)N1CC1=CC=CC=N1 NULTZQPYYBAWCL-ZEQRLZLVSA-N 0.000 claims 1
- KTFUKHNUUGSLQI-SVBPBHIXSA-N 3-[[(5s,7s)-7-methyl-2-oxo-3-[(1-phenyltriazol-4-yl)methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(CCC[C@@](C1)(CN1C2=CC(=CC=C2N=C1)C#N)C)OC1=O)N1CC(N=N1)=CN1C1=CC=CC=C1 KTFUKHNUUGSLQI-SVBPBHIXSA-N 0.000 claims 1
- UFOCGGVVMXEIIA-ZEQRLZLVSA-N 3-[[(5s,7s)-7-methyl-2-oxo-3-[(1-propan-2-yltriazol-4-yl)methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound N1=NN(C(C)C)C=C1CN1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 UFOCGGVVMXEIIA-ZEQRLZLVSA-N 0.000 claims 1
- YQVMFZOOLCNJTQ-SFTDATJTSA-N 3-[[(5s,7s)-7-methyl-2-oxo-3-[3-(trifluoromethyl)-1,2-oxazol-5-yl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(CCC[C@@](C1)(CN1C2=CC(=CC=C2N=C1)C#N)C)OC1=O)N1C1=CC(C(F)(F)F)=NO1 YQVMFZOOLCNJTQ-SFTDATJTSA-N 0.000 claims 1
- ASYSUKWBKPTZDB-GOTSBHOMSA-N 3-[[(5s,7s)-7-methyl-2-oxo-3-[5-(trifluoromethyl)pyridin-2-yl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(CCC[C@@](C1)(CN1C2=CC(=CC=C2N=C1)C#N)C)OC1=O)N1C1=CC=C(C(F)(F)F)C=N1 ASYSUKWBKPTZDB-GOTSBHOMSA-N 0.000 claims 1
- JTYZHTYUGPXOFR-GOTSBHOMSA-N 3-[[(5s,7s)-7-methyl-2-oxo-3-[6-(trifluoromethyl)pyridin-3-yl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(CCC[C@@](C1)(CN1C2=CC(=CC=C2N=C1)C#N)C)OC1=O)N1C1=CC=C(C(F)(F)F)N=C1 JTYZHTYUGPXOFR-GOTSBHOMSA-N 0.000 claims 1
- FBTIVMZAGQIVQP-ZEQRLZLVSA-N 3-[[(5s,7s)-7-methyl-3-(5-methylpyridin-2-yl)-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound N1=CC(C)=CC=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 FBTIVMZAGQIVQP-ZEQRLZLVSA-N 0.000 claims 1
- BWTLVOXPCDNKOT-DQEYMECFSA-N 3-[[(5s,7s)-7-methyl-3-[3-(1-methylpyrazol-3-yl)-1,2-oxazol-5-yl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound CN1C=CC(C2=NOC(=C2)N2C(O[C@@]3(C[C@@](C)(CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 BWTLVOXPCDNKOT-DQEYMECFSA-N 0.000 claims 1
- AZBQCBPFJAYZSQ-DQEYMECFSA-N 3-[[(5s,7s)-7-methyl-3-[3-(2-methylpropyl)-1,2-oxazol-5-yl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O1N=C(CC(C)C)C=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 AZBQCBPFJAYZSQ-DQEYMECFSA-N 0.000 claims 1
- DRYQLZOXIAJDGV-NSOVKSMOSA-N 3-[[(5s,7s)-7-methyl-3-[[4-(1-methylpyrazol-4-yl)pyridin-2-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NN(C)C=C1C1=CC=NC(CN2C(O[C@@]3(C[C@@](C)(CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=C1 DRYQLZOXIAJDGV-NSOVKSMOSA-N 0.000 claims 1
- WZGFEDBQRDKQFK-NSOVKSMOSA-N 3-[[(5s,7s)-7-methyl-3-[[6-(1-methylpyrazol-4-yl)pyridin-2-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NN(C)C=C1C1=CC=CC(CN2C(O[C@@]3(C[C@@](C)(CN4C5=CC(=CC=C5N=C4)C#N)CCC3)C2)=O)=N1 WZGFEDBQRDKQFK-NSOVKSMOSA-N 0.000 claims 1
- YRGWAIQFKIIQCB-UHFFFAOYSA-N 3-[[3-(1-benzothiophen-3-ylmethyl)-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C1=NC2=CC=C(C#N)C=C2N1CC(C1)CCCC11OC(=O)N(CC=2C3=CC=CC=C3SC=2)C1 YRGWAIQFKIIQCB-UHFFFAOYSA-N 0.000 claims 1
- RALMIIKBIJWFJI-BGOLNKOXSA-N 7-chloro-3-[[(5s,7s)-2-oxo-3-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)oxan-4-yl]methyl]-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(CCC[C@@H](C1)CN1C=2C=C(C=C(C=2N=C1)Cl)C#N)OC1=O)N1CC1(C=2ON=C(N=2)C=2C=CC=CC=2)CCOCC1 RALMIIKBIJWFJI-BGOLNKOXSA-N 0.000 claims 1
- YRGLMFFHRJCALL-SLQAJWMNSA-N 7-chloro-3-[[(5s,7s)-3-[2-methyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)propyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound O([C@@]1(C[C@@H](CN2C3=CC(=CC(Cl)=C3N=C2)C#N)CCC1)C1)C(=O)N1CC(C)(C)C(ON=1)=NC=1C1=CC=CC=C1 YRGLMFFHRJCALL-SLQAJWMNSA-N 0.000 claims 1
- KZWYQAKGFGFBQA-WRGVRERRSA-N 7-chloro-3-[[(5s,7s)-3-[[4-(3-cyclopentyl-1,2,4-oxadiazol-5-yl)oxan-4-yl]methyl]-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl]methyl]benzimidazole-5-carbonitrile Chemical compound C([C@@]1(CCC[C@@H](C1)CN1C=2C=C(C=C(C=2N=C1)Cl)C#N)OC1=O)N1CC1(C=2ON=C(N=2)C2CCCC2)CCOCC1 KZWYQAKGFGFBQA-WRGVRERRSA-N 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000002881 Colic Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000034347 Faecal incontinence Diseases 0.000 claims 1
- 206010016807 Fluid retention Diseases 0.000 claims 1
- 206010058061 Gastrointestinal oedema Diseases 0.000 claims 1
- 208000035202 High altitude pulmonary edema Diseases 0.000 claims 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000010538 Lactose Intolerance Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010016766 flatulence Diseases 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005977 kidney dysfunction Effects 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- SNTBXOPQEULPMX-KYJUHHDHSA-N tert-butyl [2-[5-[(5s,7s)-7-[(6-cyanobenzimidazol-1-yl)methyl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-3-yl]-1,2-oxazol-3-yl]-2-methylpropyl] carbonate Chemical compound O1N=C(C(C)(C)COC(=O)OC(C)(C)C)C=C1N1C(=O)O[C@@]2(C[C@@](C)(CN3C4=CC(=CC=C4N=C3)C#N)CCC2)C1 SNTBXOPQEULPMX-KYJUHHDHSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498110P | 2011-06-17 | 2011-06-17 | |
| PCT/US2012/042622 WO2013012500A1 (en) | 2011-06-17 | 2012-06-15 | Trpv4 antagonists |
| EP12814591.9A EP2721016B1 (en) | 2011-06-17 | 2012-06-15 | Trpv4 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02416B true ME02416B (me) | 2016-09-20 |
Family
ID=47558389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-120A ME02416B (me) | 2011-06-17 | 2012-06-15 | Trpv4 antagonisтi |
Country Status (38)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5969016B2 (ja) | 2011-06-17 | 2016-08-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｔｒｐｖ４拮抗薬 |
| JP5969015B2 (ja) * | 2011-06-17 | 2016-08-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｔｒｐｖ４拮抗薬 |
| JPWO2013146754A1 (ja) | 2012-03-27 | 2015-12-14 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体 |
| WO2015046193A1 (ja) | 2013-09-25 | 2015-04-02 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体 |
| RU2018144774A (ru) | 2016-05-19 | 2020-06-19 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Антагонист trpv4 |
| US10968209B2 (en) | 2016-05-19 | 2021-04-06 | Glaxosmithkline Intellectual Property (No.2) Limited | TRPV4 antagonist |
| AU2017338269B2 (en) | 2016-10-03 | 2021-03-25 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors |
| WO2018185701A1 (en) | 2017-04-06 | 2018-10-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Trpv4 antagonists as antitussive agents |
| CA3081424A1 (en) * | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Spirocyclic compounds as farnesoid x receptor modulators |
| WO2021170811A1 (en) | 2020-02-27 | 2021-09-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treating eye disease using trpv4 antagonists |
| US20230339934A1 (en) | 2020-04-30 | 2023-10-26 | Raqualia Pharma Inc. | Pyrimidin-4(3h)-one derivatives as trpv4 antagonists |
| CN111704613B (zh) * | 2020-06-23 | 2021-07-06 | 中国人民解放军军事科学院军事医学研究院 | 咪唑类衍生物及其作为trpv4抑制剂的用途 |
| TW202216143A (zh) * | 2020-07-16 | 2022-05-01 | 日商拉夸里亞創藥股份有限公司 | 作為眼疾病的治療藥之ｔｒｐｖ４抑制藥 |
| KR20250044681A (ko) | 2022-07-08 | 2025-04-01 | 액티오 바이오사이언스, 인크. | 치료용 화합물 및 방법 |
| CN120641413A (zh) * | 2023-04-18 | 2025-09-12 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| CN120225516A (zh) * | 2023-04-18 | 2025-06-27 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| CN121175303A (zh) * | 2023-04-18 | 2025-12-19 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| WO2024217452A1 (zh) * | 2023-04-18 | 2024-10-24 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| WO2024217429A1 (zh) * | 2023-04-18 | 2024-10-24 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| WO2025014818A1 (en) * | 2023-07-07 | 2025-01-16 | Actio Biosciences, Inc. | Solid forms of gsk2798745, a trpv4 antagonist |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE482945T1 (de) * | 1998-05-26 | 2010-10-15 | Chugai Pharmaceutical Co Ltd | Heterozyklische indolderivate und mono- oder diazaindol-derivate |
| US7566712B2 (en) * | 2003-07-16 | 2009-07-28 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
| CA2630617C (en) * | 2005-11-23 | 2014-03-25 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| WO2007067756A2 (en) | 2005-12-08 | 2007-06-14 | Amphora Discovery Corporation | Certain chemical entities, compositions, and methods for modulating trpv1 |
| JP5858557B2 (ja) * | 2005-12-22 | 2016-02-10 | ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | 疼痛を処置するためのｔｒｐａ１阻害剤 |
| TW200819457A (en) * | 2006-08-30 | 2008-05-01 | Actelion Pharmaceuticals Ltd | Spiro antibiotic derivatives |
| JP2010517967A (ja) * | 2007-02-01 | 2010-05-27 | グラクソ グループ リミテッド | 摂食障害の治療のための１−オキサ−３−アザスピロ［４，５］デカン−２−オン誘導体 |
| GB0707934D0 (en) * | 2007-04-24 | 2007-05-30 | Glaxo Group Ltd | Chemical compounds |
| JP2010535812A (ja) * | 2007-08-09 | 2010-11-25 | アボット・ラボラトリーズ | Ｔｒｐｖ１拮抗薬としてのテトラヒドロピリジンカルボキサミド誘導体 |
| TW200944520A (en) * | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
| WO2010011914A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Trpv4 antagonists |
| JP2012006837A (ja) * | 2008-09-30 | 2012-01-12 | Mochida Pharmaceut Co Ltd | ２−インドールアクリルアミド類縁体 |
| EP2605658B1 (en) * | 2010-08-18 | 2016-03-23 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| JP5969016B2 (ja) * | 2011-06-17 | 2016-08-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｔｒｐｖ４拮抗薬 |
| JP5969015B2 (ja) | 2011-06-17 | 2016-08-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｔｒｐｖ４拮抗薬 |
-
2012
- 2012-06-14 JO JOP/2012/0159A patent/JO3154B1/ar active
- 2012-06-15 EP EP12814591.9A patent/EP2721016B1/en active Active
- 2012-06-15 BR BR112013032391-4A patent/BR112013032391B1/pt active IP Right Grant
- 2012-06-15 PE PE2013002807A patent/PE20141943A1/es active IP Right Grant
- 2012-06-15 ES ES12814591T patent/ES2569193T3/es active Active
- 2012-06-15 UA UAA201400152A patent/UA113963C2/uk unknown
- 2012-06-15 ES ES16162808T patent/ES2688733T3/es active Active
- 2012-06-15 MY MYPI2013702447A patent/MY173521A/en unknown
- 2012-06-15 KR KR1020147000958A patent/KR101870003B1/ko active Active
- 2012-06-15 SG SG2013086483A patent/SG195106A1/en unknown
- 2012-06-15 TW TW101121449A patent/TWI538912B/zh active
- 2012-06-15 CN CN201280039690.0A patent/CN103732583B/zh active Active
- 2012-06-15 JP JP2014516020A patent/JP5969017B2/ja active Active
- 2012-06-15 AR ARP120102143A patent/AR086958A1/es active IP Right Grant
- 2012-06-15 SI SI201230564A patent/SI2721016T1/sl unknown
- 2012-06-15 HR HRP20160539TT patent/HRP20160539T1/hr unknown
- 2012-06-15 PL PL12814591T patent/PL2721016T3/pl unknown
- 2012-06-15 AU AU2012284540A patent/AU2012284540B2/en active Active
- 2012-06-15 CA CA2839743A patent/CA2839743C/en active Active
- 2012-06-15 ME MEP-2016-120A patent/ME02416B/me unknown
- 2012-06-15 UY UY0001034138A patent/UY34138A/es not_active Application Discontinuation
- 2012-06-15 MX MX2013014898A patent/MX337440B/es active IP Right Grant
- 2012-06-15 PH PH1/2013/502463A patent/PH12013502463A1/en unknown
- 2012-06-15 EP EP16162808.6A patent/EP3121177B1/en active Active
- 2012-06-15 EA EA201490037A patent/EA023616B1/ru not_active IP Right Cessation
- 2012-06-15 WO PCT/US2012/042622 patent/WO2013012500A1/en not_active Ceased
- 2012-06-15 US US14/125,378 patent/US9187464B2/en active Active
- 2012-06-15 HU HUE12814591A patent/HUE029594T2/en unknown
- 2012-06-15 PT PT128145919T patent/PT2721016E/pt unknown
- 2012-06-15 DK DK12814591.9T patent/DK2721016T3/en active
- 2012-06-15 RS RS20160417A patent/RS54858B1/sr unknown
-
2013
- 2013-11-22 ZA ZA2013/08816A patent/ZA201308816B/en unknown
- 2013-12-09 IL IL229872A patent/IL229872A/en active IP Right Grant
- 2013-12-11 CO CO13290152A patent/CO6821953A2/es active IP Right Grant
- 2013-12-13 MA MA36564A patent/MA35184B1/fr unknown
- 2013-12-16 CL CL2013003602A patent/CL2013003602A1/es unknown
- 2013-12-17 CR CR20130671A patent/CR20130671A/es unknown
- 2013-12-17 DO DO2013000307A patent/DOP2013000307A/es unknown
-
2016
- 2016-05-31 SM SM201600150T patent/SMT201600150B/it unknown
- 2016-06-21 CY CY20161100556T patent/CY1117792T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02416B (me) | Trpv4 antagonisтi | |
| JP2014518214A5 (enExample) | ||
| AU2007307679B2 (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
| US10577367B2 (en) | IRAK4 inhibiting agents | |
| CN105339370B (zh) | 用于治疗炎症性疾病的化合物和及其药物组合物 | |
| TWI748539B (zh) | Cot調節劑及其使用方法 | |
| ES2642586T3 (es) | Compuestos heterocíclicos condensados como moduladores de canales iónicos | |
| JP2021501220A5 (enExample) | ||
| US9914736B2 (en) | TrKA kinase inhibitors, compositions and methods thereof | |
| US20120225057A1 (en) | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases | |
| JP2017530960A5 (enExample) | ||
| JP2020514267A5 (enExample) | ||
| JP2014528446A5 (enExample) | ||
| RU2017105296A (ru) | Новые соединения | |
| WO2013036232A2 (en) | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases | |
| JP2013508404A5 (enExample) | ||
| JP2014525444A5 (enExample) | ||
| JP2014531465A5 (enExample) | ||
| JP2013527173A5 (enExample) | ||
| RU2018138050A (ru) | Производные тиазолопиридина как агонисты gpr119 | |
| JP2011500806A5 (enExample) | ||
| JP2016500073A5 (enExample) | ||
| HRP20180546T1 (hr) | Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti | |
| JP5036316B2 (ja) | アリールオキシ置換ベンズイミダゾール誘導体 | |
| WO2013130855A1 (en) | Indazole derivatives |